A NEW DAWN IN ALZHEIMER’S DISEASE MANAGEMENT: Recent Advances in Diagnosis and Treatment - POCN
:Home>>A NEW DAWN IN ALZHEIMER’S DISEASE MANAGEMENT: Recent Advances in Diagnosis and Treatment

A NEW DAWN IN ALZHEIMER’S DISEASE MANAGEMENT: Recent Advances in Diagnosis and Treatment

CNS | April 4, 2022


1.0 AMA PRA Category 1 Credit™
1.0 Enduring Materials, Self Study AAFP Prescribed Credit

Click to Register/login And Complete Your Free Webcourse

Launch Date:

April 4, 2022

Expiration Date:

April 4, 2023

primary audience:

Primary care physicians and other clinicians who manage patients with AD and other dementias

Relevant Terms:

Alzheimer’s disease, Disease modifying therapy, Primary care providers

course information

With the number of Alzheimer’s disease (AD) specialists limited in many parts of the country, many primary care physicians (PCPs) must provide care, often beyond their level of training or expertise, for patients with AD or early signs of AD. Too often early signs and symptoms of AD are missed or not given appropriate priority, and thus specialty referrals occur later in the course of disease. Furthermore, the difficulty in diagnosing AD and the lack of any disease modifying therapy (DMT) for AD has fostered clinical inertia among many physicians. However, the approval of the first blood test for AD in November 2020 and the first DMT, aducanumab, in June 2021, should begin to provide the armamentarium that has been missing from AD management since it was first characterized.

Given that 85% of initial AD diagnoses are made by non-specialists, yet almost 40% of PCPs are not comfortable making the diagnosis and 50% do not consider medical professionals prepared to care for people with AD, it is vital that PCPs receive education to help them stay abreast of these recent developments, be able to integrate them into practice where appropriate and in an evidence-based manner, and be aware of emerging developments in AD diagnosis and treatment.

The educational program, “A NEW DAWN IN ALZHEIMER’S DISEASE MANAGEMENT: Recent Advances in Diagnosis and Treatment” will provide the latest AD clinical developments in a manner that is most relevant to the primary care setting and will provide access to AD resources and experts to help prepare them for the potential sea change in AD management.

Welcome and Introduction
Detecting Mild Cognitive Impairment and Decline Early in the Course of Disease

Current and Emerging Therapies for AD
Q & A Session and Activity Roundup


Sharon Cohen, MD, FRCPC
Neurologist and Medical Director
Toronto Memory Program
Toronto, Canada

Sharon Cohen, MD, FRCPC is a behavioral neurologist known for her excellence in patient care, teaching, and clinical research. She completed her neurology residency and behavioral neurology fellowship at the University of Toronto. She is the medical director and site principal investigator of Toronto Memory Program, a community-based medical facility which she established in 1996 for the purpose of enhancing diagnosis, medical care, and therapeutic options for individuals with, or at risk for, Alzheimer’s disease and related disorders. Her memory clinic and research site are among the most active in Canada.Dr. Cohen has over 28 years of experience in clinical research and has been a site PI for over 180 pharmacological trials. In addition to her focus on Alzheimer’s disease, she has also participated in pharmacological trials for acute stroke, frontal-temporal dementia, Parkinson’s disease dementia, Lewy body disease, Huntington’s disease, and vascular dementia. Her research site has been credited as a “go to” Centre for Alzheimer’s trials and has been awarded for superior performance and quality in clinical research.

Dr. Cohen represents Canada on international advisory boards and steering committees and is a consultant to a wide range of stakeholders in dementia, including government organizations and patient advocacy groups. She is a frequent lecturer and contributes to media events including those on medical ethics. She is known for her advocacy of individuals with neurodegenerative diseases.

Despite holding academic and hospital appointments, Dr. Cohen chooses to practice in the community, in keeping with her belief that dementia care and clinical research are best offered in the real-world setting.

R. Scott Turner, MD, PhD
Professor of Neurology and Director, Memory Disorders Program
Georgetown University Medical Center
Washington, DC

R. Scott Turner, MD, PhD is a Professor of Neurology and Director of the Memory Disorders Program at Georgetown University Medical Center in Washington, DC. Dr. Turner and his team are dedicated to providing state-of-the-art clinical services for individuals affected by Alzheimer’s disease (AD) and related disorders and to conducting research aimed at improving treatment options for AD. He previously served as Chief of the Neurology Service at the VA Medical Center and Associate Professor of Neurology at the University of Michigan in Ann Arbor.Dr. Turner was awarded MD and PhD degrees from Emory University in Atlanta. He then completed an internship in internal medicine and a residency and fellowship in neurology at the University of Pennsylvania in Philadelphia. Dr. Turner has authored or coauthored more than 100 peer-reviewed publications including editorials, reviews, and book chapters. Among numerous prestigious awards, Dr. Turner was a Howard Hughes Medical Scholar and a Beeson Scholar. He is an elected Fellow of the American Neurological Association and a recipient of a 2012 Washington Monument Award from the National Capital Area Chapter of the Alzheimer’s Association.

The intended audience for this educational initiative is primary care physicians and other clinicians who manage patients with AD and other dementias.

At the conclusion of this education, participants should be able to:

  • Integrate validated assessment tools and discuss available biomarker testing to diagnose Alzheimer’s disease early in the course of disease
  • Make timely and appropriate referrals to AD specialists for patients with symptoms of AD or other dementias
  • Assess the safety and efficacy profiles of current and emerging treatment options for Alzheimer’s disease

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for clinicians.

The Potomac Center for Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Clinicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding CME/MOC/AAFP credit or the evaluation, please email contact@potomacme.org.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PCME’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, A NEW DAWN IN ALZHEIMER’S DISEASE MANAGEMENT: Recent Advances in Diagnosis and Treatment has met the requirements as a Lifelong Learning CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:


ABMS Lifelong Learning CME Activity
Family Medicine


The AAFP has reviewed A NEW DAWN IN ALZHEIMER’S DISEASE MANAGEMENT: Recent Advances in Diagnosis and Treatment, and deemed it acceptable for up to 1.00 Enduring Materials, Self-Study AAFP Prescribed credits. Term of approval is from 04/04/2022 to 04/04/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This session is approved for 1.0 AAFP Prescribed credits.

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other relevant professional organizations, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of an accredited continuing education program provided by the Potomac Center for Medical Education are required to disclose to PCME all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by PCME in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by PCME to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by PCME.

Faculty, Authors, and Content Developers
The faculty, authors and content developers reported the following relevant financial relationships with ineligible companies:

Sharon Cohen, MD, FRCPC: Contracted Research: AbbVie, AgeneBio Inc., Alector, Anavex Canada Ltd., Alzheon, Biogen, Eisai Inc., Genentech Inc., Hoffman La Roche Ltd., Janssen, Shanghai Green Valley Pharmacetical Co. Ltd, Vielight Inc.,

R. Scott Turner, MD, PhD: Consulting Fee: Jupiter Neurosciences, KiefeRx, NeuroNascent, Stock Options: Jupiter Neurosciences; Speaker’s Bureau: Biogen; Contracted Research: Alector, Biogen, Eisai, Janssen, Lilly, Roche

Planners and Managers
The planners and managers reported the following relevant financial relationships with ineligible companies:

Chad Williamson, MS, MBA, CMPP: Has no relevant relationships

Content Reviewers
The content reviewers reported the following relevant financial relationships with ineligible companies:

Katie Propst, PhD: Has no relevant relationships

The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac & Windows): Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

There is no fee for this activity. To receive credit, participants must register, view the CME/AAFP/MOC activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is one hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.

Jointly provided by the Potomac Center for Medical Education and Rockpointe

This program is supported by an independent educational grant from Eisai, Inc.

Go to Top